Furthermore, due to financial limitations, we were unable to measure the levels of additional biomarkers associated with DCM, such as galectin-3 and fibroblast growth factor 23, which could have provided further insights into the pathophysiological changes induced by TMZ therapy. The gene discussed is FGF23; the disease is familial dilated cardiomyopathy.